Oxford Pharm Gp Share Discussion Threads

[halfpenny] 30/10/2015 11:58

sniff sniff sniff anyone with news on OXP.....

[halfpenny] 30/10/2015 11:21

NOTE the following statement they made a few weeks ago....

"Headline results on the second phase are expected to be released in Q4 2015, along with complete PK data and further taste masking assessments."

should be soon very soon in my view and OXP may fly....early XMAS on the way..

[halfpenny] 30/10/2015 11:02

well well well, what do we have with OXP?
Fantastic opportunity to make lots and lots of gains with TRIAL results due out after THIS week.
WPCT Woodford bought a shed load of OXP about 10 MILLIOM pounds worth at 10p, yes I did say about 10 MILLION....at 10p
I am in and buying a few thousand......no brainer to me.....and cheap as chips at 6p... a 40% discount from the price Woodford paid....for 100 MILLION shares wow!!

see you at the top....

[rocketblast] 19/8/2015 15:27

I am in Woodford fund which has "rocketed" to about £1.20....he has some interesting selections....

[rocketblast] 19/8/2015 15:24

i have bought in after a review and also I see Woodford (WPCT fund) has a good stake in OXP. He would have carried out extensive research and would have got these at a much higher price than today....so i guess we are now waiting for some interesting news flow....these will "Rocket" hope you enjoyed the honey above...

i will also top up when funds become available as they are a no brainer...

[rocketblast] 17/8/2015 20:12

interesting insight o why did Woodford invest as part of his WPCT fund?

what does he know or are we all in the same boat without a paddle ????
arghhhhh

[timbo003] 12/8/2015 08:01

I don’t think shareholders should find much comfort in this morning’s RNS concerning OXP001(2).

They are still struggling to get rapid and complete absorption for an ibuprofen formulation as evidenced by their remarks on Cmax: “the maximum level of drug concentration in plasma (Cmax) appears to be lower compared to Brufen® but remains well within the range which the drug has therapeutic effect”, i.e. they have failed to show bioequivalence again on Cmax.

They go on to say: “The Company believes this preliminary PK data represents an acceptable clinical profile suitable for commercialisation”.I wonder if the regulators will agree with that and also prospective commercial partners? I know I wouldn’t if I was assessing the data package.

Furthermore this was a pilot study (n=10) so it’s underpowered again, so there remains a huge question mark over the likely outcome of the PK in the follow on study. Why didn’t they just use a decent number in the first place?

Also note that OXP001(2) is a chewable tablet which has a host of disadvantages compared to a small swallow tablet, especially for chronic use (as outlined in this previous post):


I found this comment in this morning’s RNS rather odd: ” A prior study in 2014 demonstrated significant GI side-effect benefits, compared to Brufen®, using an early version of OXP001 for which the PK profile has since been optimised for immediate release and complete drug absorption”.

....hang on a moment, if the product in the 2014 study was “optimised for immediate release and drug absorption” why did it fail and why are we not using it again for this study? I reckon whoever is writing these RNS announcements is losing the plot and we can now assume that the earlier ibuprofen swallow tablet (OXP001) is dead and buried and OXP001(2) is getting ready to receive the last rites.

[votiem] 03/8/2015 09:06

Okay... £84m

[votiem] 03/8/2015 08:59

Excellent analysis Tim. What bothers me about this jam tomorrow stock is that in five years none of the big boys e.g. GSK and AZ are paying any money for their research. The Capitalisation is around £840m on revenues of what, £700,000 last year?

Yep - Woodford messed up.

[burbelly] 01/8/2015 11:49

Yeah well done Tim but what a great share this has been after all that's what it's all about on here

[achillesheel] 31/7/2015 23:09

Top line its all window dressing the only thing you need to take from the rns is that the lanza scores were similar in reality the oxp could have been slightly worse, the formulation offers no reduced gi effects and at a reduced level of absorption so basically it sucks a lot of people owe timbo an apology as he has called it correctly from day one.

[supernumerary] 31/7/2015 10:52

gnmartin - he's an acknowledged world expert in the subject - it was obvious from the start that he was right.

I don't really understand these results:

'In the study both OXP005 and Naprosyn(R) exhibited a similar Lanza score while OXP005 exhibits a moderate (c. 26%) reduction in total erosions, albeit at a non statistically significant level.

OXP005 meets the primary endpoint of reduced erosions exhibiting a major (c. 38%) reduction of total erosions which is statistically significant after accounting for ineligible subjects.'

What does this mean - was it 26% or was it 38%? Or is the difference just a game played with the handling of the 'ineligible subjects'?

[gnnmartin] 31/7/2015 09:05

Timbo: damn you Red Baron, you were right. :-O

[timbo003] 31/7/2015 08:14

The market seems to be grossly underestimating exactly how bad these results really are.

OXP005 has failed on its primary objective and this was in a highly controlled pilot study, it would stand no chance in a real clinical.

There is no further work to do, the formulation was already optimised, OXP005 will be dropped and this does not bode at all well for OXP001.

[timbo003] 31/7/2015 08:04

Interesting to see that they did conduct simultaneous PK (although the outline protocol failed to mention this)

The Cmax was lower again, albeit is was just within the acceptable limits, if I were involved in partnering negotiations with them, this would be another big red flag for me

If I were a shareholder, I would now be asking the question, would now be good time to quit this folly and return the cash back to shareholders?

[timbo003] 31/7/2015 07:58

I think this should trade at close to cash in the bank now

Now much do they have £30M?

In which case 2 - 3p per share seems about right

[timbo003] 31/7/2015 07:16

Hopefully no one is too over exposed to this one (apart from Woodford) and those of you who got in down at 4p managed to take some chips off the table.

It just goes to show that Neil Woodford doesn't get it right every time.


more later.....

[gnnmartin] 30/7/2015 11:54

The share price suggests that others share your view, timbo.

[timbo003] 30/7/2015 09:36

OXP seem to be leaving the announcement of the OXP005 results to the last minute (tomorrow is the last working day in July) which suggests to me that they have probably been conducting some secondary analysis, which normally means that the results are not clear cut (either way).

Just for the record, I think they will see some reduction in GI irritancy with OXP005 vs the control, although I suspect it will be a smaller effect than they observed for OXP001 (I would base this assumption on the relative PK, lipophilicity and likely relative affinity towards Mg/Al hydroxide for ibuprofen and naproxen).

As I have commented before, it doesn't look like they are doing a simultaneous PK study this time, so even if OXO005 does reduce GI irritancy vs control there will still be a big, big question mark over whether or not it is bioequivalent to the control with respect to both Cmax and AUC.

I also suspect size of tablet may be an issue, but not knowing how much Mg/AL OH they are adding to the formula that remains an unanswered question for now.

It does make me wonder why they are going to all this trouble. Especially when there is a good product already out there with excellent clinical data: Vimovo


(see my earlier posts on Pozen)

Also I suspect you would see the same sort of effect if you merely co-administered generic naproxen, or generic ibuprofen with the antacid Maalox (which contains Mg/AL OH formulated as a suspension or tablet)


It would certainly be a lot cheaper for the patients and/or the healthcare providers and those treatments are available now, so no need to wait for OXP's developments

[timbo003] 16/7/2015 09:49

Regarding this morning’s RNS release; there are no details on the clintrial.gov data base for the new OXP001 study which is odd. When you search for Oxford Pharmascience, only three (completed) trials come up.




I have also checked the UK and European clinical trial data bases and there is nothing there either


The RNS seems to confirm that OXP001 has now morphed into the chewable format only (previously it was a conventional tablet). I’m not sure why they gave up with the conventional tablet, my guess would be it was either down to the size (too big to swallow), or they just couldn’t get it to perform in the in vitro tests.

It’s worth mentioning that it will be very difficult to blind the study properly if they are comparing a chew tablet vs a conventional ibuprofen tablet (Brufen), in fact it wouldn’t surprise me if the study is unblinded, which is not a big deal for this pilot study as all the parameters being comparted are objective, but it would be an issue for a subsequent larger pivotal study (if they ever get there) where one of the primary parameters to be compared will be pain relief (which is highly subjective).

Leaving those issues aside, a chew tablet is probably not a good format for an analgesic for chronic use (GI safety is not an issue for acute use, so there is no clinical need for the product). Some patients won’t like the flavour, some patients will be diabetic (so sugar free?) some patients will have low tolerance to sugar substitutes (GI problems), most patients probably won’t like the chalky consistency. The packaging is likely to be bulky and expensive. I cannot think of any NSAID where a chewable format has done well commercially, the preferred format is a simple swallow tablet.

They mention that the results from the OXP005 endoscopy study should be due at the end of the month, my guess is they now know the outcome of that study but are preparing the final clinical report. I suspect it will not live up to some investor’s expectations. In which case it is quite a prudent move to get this OXP001 study underway now, rather than have questions asked about the whole technology, should the OXP005 results disappoint.

[supernumerary] 26/6/2015 11:19

timbo - had a read and very unconvinced - I've watched deltex medical (DEMG) for too long to have much faith in the business model. I wish you luck because I think you'll need it.

[timbo003] 26/6/2015 08:48

Another AGM report (which I attended yesterday) from another Woodford favorite: Sphere Medical (SPHR)


The shares are sitting close to an all time low, Neil Woodford and Chris Evans are both recent investors (Sphere were Woodford's first investment for his Patient Capital Trust)

Orders of magnitude better value than OXP, far less risky and with much greater multi-bagger potential IMO.

[timbo003] 24/6/2015 08:19

I attended the Synairgen (SNG) AGM on Monday (another Woodford favourite) which I mentioned in my last post above, the link to my AGM report is below, which may be of interest to some here:


It's the AGM for Sphere Medical (SPHR) tomorrow (another very recent Woodford investment), I shall be attending that one too (report to follow), the shares are currently trading at close to their all time low.